Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis.

Chong-Kin Liam Azura Rozila Ahmad Te-Chun Hsia Jian-Ying Zhou Dong Wan Kim Ross Andrew Soo Ying Cheng Shun Lu Sang Won Shin James Chih-Hsin Yang Yiping Zhang Jun Zhao Karin Berghoff Rolf Bruns Andreas Johne Yi-Long Wu

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Final analysis of INSIGHT suggests improved PFS and OS with tepotinib plus gefitinib versus chemotherapy in a subgroup of patients with MET-amplified EGFR-mutant NSCLC, after progression on EGFR inhibitors.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
advanced non small cell lung cancer
brain metastases
locally advanced
randomized controlled trial
squamous cell carcinoma
study protocol
chemotherapy induced